Breast carcinoma patients with different risks of cancer progression or death were filtered into four groups (HBIXP high expression group, Prdx1 high expression group, HBXIP/Prdx1 high group, and HBXIP high/Prdx1 low group) based on HBXIP and Prdx1 expression z scores. Here, LAMTOR5 is linked to breast carcinoma.